Perspective Therapeutics: EPS paint estimates um 0.16 $

Investing.com – Perspective Therapeutics (NYSE: ) reported EPS of -$0.1800 four years ago, $0.16 worse than analyst estimates of -$0.0200.

The costs for the four-year purchase price are worth $530K, the detailed estimates cost $87.75K.

The Perspective Therapeutics share price is officially set at a closing price of $12.09. In the last 3 months the performance was at minus -20.9800%, in the last 12 months at plus 152.9300%.

Perspective Therapeutics has had positive EPS revisions and negative EPS revisions in the last 90 days. The reactions of the action courses of Perspective Therapeutics to the previous generation of health care can be a fact here.

InvestingPro supports the financing of Perspective Therapeutics on the Fundamental Fund financing feature as “through-going”.

Information about Perspective Therapeutics can be found here.

All balance dates and results can be found in our balance calendar, for a large number of companies in a real-time activated world.